Background
==========

Colorectal cancer (CRC) is the second leading cause of cancer death in developed countries \[[@B1]\]. Familial adenomatous polyposis and Lynch syndrome are the most frequent hereditary CRC syndromes with a more aggressive presentation, earlier onset and strong familial aggregation. However, they only correspond to a minority of the total CRC burden (\~5%). Most genetic components involved in these less frequent hereditary forms were successfully identified in the past two decades and they correspond to rare, highly penetrant alleles that predispose to CRC. Genetic association analyses have been the strategy to identify predisposing CRC alleles in the last decade, firstly by studying a small number of such variants or single nucleotide polymorphisms (SNP) using candidate-gene approaches \[[@B2]\], and lately with an unbiased strategy by genome-wide association studies (GWAS) \[[@B3],[@B4]\].

From the EPICOLON consortium \[[@B5]\], several genetic association candidate-gene efforts have been pursued since 2005 aiming to identify genetic susceptibility variants for CRC. In this manner, SNPs/genes were selected to be studied from the previously identified category (variants linked to CRC risk in previous studies), from human syntenic CRC susceptibility regions identified in mouse, from the CRC carcinogenesis-related pathways Wnt and BMP, from regions 9q22 and 3q22 with positive linkage in CRC families, and from the mucin gene family \[[@B6]-[@B8]\]

SNPs in genes selected in the previously identified category (*ADH1C*, *APC*, *CCDN1*, *IL6*, *IL8*, *IRS1*, *MTHFR*, *PPARG*, *VDR*and *ARL11*) have been analyzed in previous independent genetic association studies and they are *a priori*attractive candidates for genetic susceptibility to CRC \[[@B6],[@B9]-[@B24]\]. The expression of most genes in this category are altered in CRC and they appear to be involved in important processes for CRC risk such as hereditary CRC (*APC*), alcohol metabolism (*ADH1C*), inflammation (*IL6*, *IL8*), cell cycle regulation (*CCDN1*), energy balance (*IRS1*, *PPARG*), methylation (*MTHFR*), vitamin D (*VDR*), and the RAS superfamily (*ARL11*). On the other hand, mucins are protein constituents of the mucous barrier that protects human epithelia from adverse conditions, and they are highly glycosylated by GALNT proteins. Mucins and GALNTs, members of the mucin gene family, can be found deregulated in CRC and other neoplasms and, although also interesting candidates, they have not been previously evaluated for CRC genetic susceptibility \[[@B25]\].

Here, we report results from a case-control association study for CRC risk in the EPICOLON cohort for previously identified SNPs in *ADH1C*, *APC*, *CCDN1*, *IL6*, *IL8*, *IRS1*, *MTHFR*, *PPARG*, *VDR*and *ARL11*, and selected variants within the mucin gene family.

Methods
=======

Study populations
-----------------

Studied subjects were mainly from EPICOLON, a prospective, multicenter, nationwide Spanish initiative <http://www.aegastro.es/aeg/ctl_servlet?_f=16&grupo=4>\[[@B5]\], comprised of two stages (2000-2001 and 2006-2008), where CRC cases and matched healthy controls were collected. DNA samples were extracted as previously described \[[@B6],[@B7]\]. EPICOLON stage 1 corresponded to 515 CRC cases and 515 controls, whereas EPICOLON stage 2 consisted of 901 CRC cases and 909 controls. Additionally, an independent cohort of 549 CRC cases and 599 controls (MCC-Spain; <http://www.creal.cat>) was available for further replication of putative positive hits in EPICOLON. Cases and controls were matched for sex and age (± 5 years) and controls were negative for personal and family cancer history. All samples were obtained with informed consent reviewed by the ethical board of the corresponding hospital.

Gene and SNP selection
----------------------

Selected SNPs were included in the previously identified category if they corresponded to genetic variants linked to CRC risk by previously published independent studies, or in the mucin gene family if located on genes encoding for mucins and GALNT proteins. Mucins are protein constituents of the mucous barrier highly glycosylated by GALNT proteins. One relevant previously identified SNP was studied in each of the following genes: *ADH1C*, *APC*, *CCDN1*, *IL6*, *IL8*, *IRS1*, *MTHFR*, *PPARG*, *VDR*and *ARL11*. For the mucin gene family, 1-2 SNPs were selected from each of the following genes: *MUC7*, *MUC12*, *MUC13*, *MUC15*, *MUC16*, *MUC17*, *MUC19*, *MUC21*, *GALNT1*, *GALNTL2*, *GALNT10*, *GALNT14*, *GALNT4*and *OVGP1*. Mucin gene selection did not intentionally include *GALTN12*. This gene is located on the 9q22 region and it was studied in our candidate-gene approach for regions with positive linkage in CRC families (Abulí et al., manuscript in preparation). SNP selection in the mucin gene family was performed using Pupasuite, a web tool for the selection of genetic variants with potential phenotypic effect (pupasuite.bioinfo.cipf.es) \[[@B26]\]. SNPs were always prioritized if they were coding, evolutionary conserved in mouse and SNP minor allele frequency (MAF) was above 5%. Other selected SNPs with a putative regulatory effect were in promoter, intronic or 3\'-UTR regions. A complete list of SNP and genes analyzed in the present study is detailed in Table [1](#T1){ref-type="table"}.

###### 

SNPs genotyped in EPICOLON from the previously identified category and the mucin gene family to evaluate their implication in CRC genetic susceptibility.

  Gene        SNP ID       Chr   Position\*   Category                SNP type             Alleles
  ----------- ------------ ----- ------------ ----------------------- -------------------- ---------
  *MTHFR*     rs1801133    1     11856378     Previously identified   Missense (A222V)     C/T
  *IRS1*      rs1801278    2     227660544    Previously identified   Missense (G971R)     A/G
  *PPARG*     rs1801282    3     12393125     Previously identified   Missense (P12A)      C/G
  *IL8*       rs4073       4     74606024     Previously identified   Promoter             A/T
  *ADH1C*     rs698        4     100260789    Previously identified   Missense (I350V)     A/G
  *APC*       rs459552     5     112176756    Previously identified   Missense (V1822D)    A/T
  *IL6*       rs1800795    7     22766645     Previously identified   Promoter             C/G
  *CCDN1*     rs9344       11    69462910     Previously identified   Synonymous (P241P)   A/G
  *VDR*       rs2228570    12    48272895     Previously identified   Missense (M1T)       C/T
  *ARL11*     rs3803185    13    50205025     Previously identified   Missense (C158R)     A/G
                                                                                           
  *OVGP1*     rs10067      1     111957311    Mucin family            Missense (H604Q)     C/G
  *GALNT14*   rs2288101    2     31135184     Mucin family            Missense (Q469K)     A/C
  *GALNT14*   rs11676188   2     31352788     Mucin family            Intronic             C/G
  *GALNTL2*   rs2102302    3     16215650     Mucin family            Promoter             A/G
  *MUC13*     rs12732      3     124624568    Mucin family            3\'-UTR              C/T
  *MUC13*     rs4679392    3     124646594    Mucin family            Missense (I99T)      A/G
  *MUC7*      rs6826961    4     71346701     Mucin family            Missense (N80K)      C/G
  *GALNT10*   rs6580076    5     153783753    Mucin family            Synonymous (A382A)   C/T
  *GALNT10*   rs2277937    5     153799165    Mucin family            3\'-UTR              C/T
  *MUC21*     rs1634730    6     30954245     Mucin family            Missense (V98A)      C/T
  *MUC12*     rs11766125   7     100648117    Mucin family            Missense (T4758R)    C/G
  *MUC17*     rs4729656    7     100701610    Mucin family            3\'-UTR              A/T
  *MUC15*     rs15783      11    26586801     Mucin family            Missense (T229I)     A/G
  *MUC15*     rs11029621   11    26596998     Mucin family            3\' near gene        A/G
  *MUC19*     rs2933353    12    40857943     Mucin family            Missense (G1803A)    A/C
  *GALNT4*    rs2230283    12    89916811     Mucin family            Missense (V506I)     A/G
  *GALNT1*    rs17647532   18    33234072     Mucin family            Promoter             C/T
  *MUC16*     rs1862458    19    9069792      Mucin family            Missense (S5885F)    A/G

SNP ID, single nucleotide polymorphism identification.

Chr: Chromosome; UTR: untranslated region. \*According to NCBI build 37.1 available at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp>.

High-throughput genotyping in EPICOLON cohorts was performed according to manufacturer\'s instructions with the TaqMan allelic discrimination and SNPlex™ systems (Applied Biosystems, Foster City, USA), and single-base primer extension chemistry matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) genotyping platform (Sequenom Inc., San Diego, USA). Genotyping in the MCC-Spain cohort was performed using the VeraCode technology (Illumina, San Diego, USA). Genotyping was performed at the Santiago de Compostela and Barcelona nodes of the Spanish National Genotyping Centre <http://www.cegen.org>, and at the Genome Analysis Platform of the CIC-BioGUNE <http://www.cicbiogune.es>.

Statistical methods
-------------------

As quality control, genotyping success was set above 90% for SNPs. Allelic frequency description and Hardy-Weinberg equilibrium test were performed using SNPator, a web-based tool offered by the Bioinformatics division of the Spanish National Genotyping Centre (bioinformatica.cegen.upf.es) \[[@B27]\]. All SNPs analyzed had a genotype success rate \> 90%. The genotype frequencies of all variants in the control population fitted the Hardy-Weinberg equilibrium (*P*\> 0.01), supporting absence of genotyping artifacts. There was no sign of underlying population stratification in EPICOLON as tested by an independent study \[[@B7]\]. Genotype analysis was carried out using the SNPassoc R library \[[@B28]\]. Inter-group comparisons of genotype frequency differences were performed by regression analysis for codominant, dominant, recessive and log-additive models of inheritance. We estimated the crude odds ratio (OR) and their 95% confidence intervals (95% CIs). As expected, results did not change after sex and age adjustment. The best genetic or inheritance model was selected using the Akaike information criteria. To address the issue of multiple testing, we used Bonferroni correction (*P*= 0.0125 for four SNPs). Study power was estimated with CaTS software \[[@B29]\].

Results
=======

Twenty-eight SNPs, ten from the previously identified category and 18 from the mucin gene family, were successfully genotyped in EPICOLON stage 1. Results in EPICOLON stage 1 are shown in Additional File [1](#S1){ref-type="supplementary-material"}. Four SNPs were significant with a *P*-value \< 0.05 in any of the tested inheritance models: rs698 in *ADH1C*(OR = 1.63, 95% CI = 1.06-2.50, *P*-value = 0.02, recessive, AA-AG vs GG), rs1800795 in *IL6*(OR = 1.62, 95% CI = 1.10-2.37, *P*-value = 0.01, recessive, GG-GC vs CC), rs3803185 in *ARL11*(OR = 1.58, 95% CI = 1.17-2.15, *P*-value = 0.007, codominant, GG vs AG vs GG), and rs2102302 in *GALNTL2*(OR = 1.20, 95% CI = 1.00-1.44, *P*-value = 0.04, log-additive 0, 1, 2 alleles).

In the EPICOLON stage 1 cohort, a liberal *P*-value threshold (*P*-value \< 0.05) was used to avoid false-negative results. We then validated statistically-significant stage 1 results by replicating them in another independent CRC cohort (EPICOLON stage 2). Further replication in stage 2 was performed only for significant SNPs in stage 1. Results for rs698, rs1800795, rs3803185, and rs2102302 in EPICOLON stage 2 are shown in Additional File [2](#S2){ref-type="supplementary-material"}. Only rs3803185 maintained statistical significance in stage 2 (OR = 1.34, 95% CI = 1.06-1.69, *P*-value = 0.01, recessive model, AA-AG vs GG). In order to improve statistical power, results for EPICOLON stages 1 and 2 were also analyzed jointly for these four SNPs. Results were only significant for rs3803185 (OR = 1.12, 95% CI = 1.00-1.25, *P*-value = 0.04, log-additive 0, 1, 2 alleles) and borderline significant for rs698 and rs2102302 (Table [2](#T2){ref-type="table"}).

###### 

SNPassoc results for previously identified and mucin SNPs in EPICOLON cohorts.

  EPICOLON stages 1+2 (1,416 CRC cases and 1,424 controls)                                                           
  ---------------------------------------------------------- ---------- ------ ------- ------ ------ ------- ------- -------------
  ***ADH1C***                                                                                                        
  **rs698**                                                  Controls   \%     Cases   \%     OR     lower   upper   *P*-value
                                                                                                                     
  Codominant                                                                                                         
  A/A                                                        629        46.1   616     44.2   1.00                   0.13565
  A/G                                                        610        44.7   620     44.4   1.04   0.89    1.22    
  G/G                                                        125        9.2    159     11.4   1.30   1.00    1.69    
  Dominant                                                                                                           
  A/A                                                        629        46.1   616     44.2   1.00                   0.29181
  A/G-G/G                                                    735        53.9   779     55.8   1.08   0.93    1.26    
  Recessive                                                                                                          
  A/A-A/G                                                    1239       90.8   1236    88.6   1.00                   0.05243
  G/G                                                        125        9.2    159     11.4   1.28   1.00    1.63    
  Log-Additive                                                                                                       
  0, 1, 2                                                    1364       49.4   1395    50.6   1.10   0.98    1.24    0.09043
                                                                                                                     
                                                                                                                     
  ***IL6***                                                                                                          
  **rs1800795**                                              Controls   \%     Cases   \%     OR     lower   upper   *P*-value
                                                                                                                     
  Codominant                                                                                                         
  G/G                                                        593        42.7   586     41.7   1.00                   0.7950
  G/C                                                        623        44.9   635     45.2   1.03   0.88    1.21    
  C/C                                                        172        12.4   184     13.1   1.08   0.85    1.37    
  Dominant                                                                                                           
  G/G                                                        593        42.7   586     41.7   1.00                   0.5862
  G/C-C/C                                                    795        57.3   819     58.3   1.04   0.90    1.21    
  Recessive                                                                                                          
  G/G-G/C                                                    1216       87.6   1221    86.9   1.00                   0.5763
  C/C                                                        172        12.4   184     13.1   1.07   0.85    1.33    
  log-Additive                                                                                                       
  0, 1, 2                                                    1388       49.7   1405    50.3   1.04   0.93    1.16    0.5034
                                                                                                                     
                                                                                                                     
  ***ARL11***                                                                                                        
  **rs3803185**                                              Controls   \%     Cases   \%     OR     lower   upper   *P*-value
                                                                                                                     
  Codominant                                                                                                         
  A/A                                                        359        26.9   301     23.7   1.00                   0.12263
  A/G                                                        686        51.4   666     52.4   1.15   0.95    1.39    
  G/G                                                        289        21.7   304     23.9   1.26   1.01    1.57    
  Dominant                                                                                                           
  A/A                                                        359        26.9   301     23.7   1.00                   0.06417
  A/G-G/G                                                    975        73.1   970     76.3   1.18   0.99    1.41    
  Recessive                                                                                                          
  A/A-A/G                                                    1045       78.3   967     76.1   1.00                   0.15480
  G/G                                                        289        21.7   304     23.9   1.14   0.95    1.37    
  log-Additive                                                                                                       
  0, 1, 2                                                    1334       51.2   1271    48.8   1.12   1.00    1.25    **0.04338**
                                                                                                                     
                                                                                                                     
  ***GALNTL2***                                                                                                      
  **rs2102302**                                              Controls   \%     Cases   \%     OR     lower   upper   *P*-value
                                                                                                                     
  Codominant                                                                                                         
  A/A                                                        579        42.1   538     39.0   1.00                   0.16056
  A/G                                                        607        44.1   624     45.3   1.11   0.94    1.30    
  G/G                                                        189        13.7   217     15.7   1.23   0.98    1.55    
  Dominant                                                                                                           
  A/A                                                        579        42.1   538     39.0   1.00                   0.0971
  A/G-G/G                                                    796        57.9   841     61.0   1.14   0.98    1.32    
  Recessive                                                                                                          
  A/A-A/G                                                    1186       86.3   1162    84.3   1.00                   0.14317
  G/G                                                        189        13.7   217     15.7   1.17   0.95    1.45    
  log-Additive                                                                                                       
  0, 1, 2                                                    1375       49.9   1379    50.1   1.11   1.00    1.24    0.0558

Significant *P*-values (\< 0.05) are highlighted in bold.

OR, odds ratio

In order to further investigate rs3803185, we were able to genotype it additionally outside EPICOLON in a cohort from a Spanish multicase-control population study for common neoplasms (MCC-Spain). This variant was not significantly associated with CRC risk in this independent cohort. Pooled analysis for rs3803185 in the EPICOLON and MCC-Spain cohorts still showed borderline significance (OR = 1.08, 95% CI = 0.98-1.18, *P*-value = 0.09, log-additive 0, 1, 2 alleles).

Associations of rs698, rs1800795, rs3803185 and rs2102302 were also evaluated in 2 cohorts described in a previous GWAS \[[@B30]\], either by checking the original variant or a proxy SNP highly correlated with it (r^2^\> 0.7) (Table [3](#T3){ref-type="table"}). Interestingly, rs3803185 showed again significance in one of the GWAS (*P*= 0.03). However, it should be commented that weak associations observed in our study would have not been present if Bonferroni correction for multiple testing was applied and, therefore, they should be considered as not statistically significant.

###### 

Association results for four selected SNPs evaluated in two external GWAS (CORGI and VQ58), either by checking the original variant or a proxy SNP highly correlated with it (r^2^\> 0

                  Present in I5?   Present in I3?   Proxy       r^2^and D\'   *P*-value (CORGI)   *P*-value (VQ58)
  --------------- ---------------- ---------------- ----------- ------------- ------------------- ------------------
  **rs698**       no               no               rs1789924   1.000 1.000   0.1806              0.1658
  **rs1800795**   no               no               rs1554606   0.868 0.932   0.1743              0.3346
  **rs3803185**   no               no               rs4942859   0.716 1.000   0.5943              **0.03525**
  **rs2102302**   no               no               rs2730351   0.853 1.000   0.1447              0.4666

Significant *P*-values (\< 0.05) are highlighted in bold.

I5, Illumina HumanHap550; I3 Illumina HumanHap300.

Discussion
==========

Ten previously identified SNPs in *ADH1C*, *APC*, *CCDN1*, *IL6*, *IL8*, *IRS1*, *MTHFR*, *PPARG*, *VDR*and *ARL11*, and 18 selected variants in the mucin gene family were evaluated with a genetic association strategy. CRC cases and matched controls collected in two independent stages within the EPICOLON consortium were genotyped in order to evaluate its potential association with CRC risk. Mucins and GALNTs, members of the mucin gene family, have not been previously evaluated for CRC genetic susceptibility.

Significant results for previously identified SNPs in independent cohorts regarding CRC risk were previously reported for *APC*\[[@B11],[@B12]\], *CCDN1*\[[@B13],[@B14]\], *IL6*and *IL8*\[[@B15],[@B16]\], *IRS1*\[[@B17]\], *MTHFR*\[[@B18]-[@B20]\], *PPARG*\[[@B21]\], and *VDR*\[[@B22],[@B23]\]. Remarkably, variants in *MTHFR*and *CCDN1*were additionally supported by meta-analyses of several individual studies \[[@B31]\]. However, none of them was confirmed in our cohort.

In our study, four SNPs were significant in EPICOLON stage 1 (rs698 in *ADH1C*, rs1800795 in *IL6*, rs3803185 in *ARL11*, and rs2102302 in *GALNTL2*), but only rs3803185 achieved statistical significance in EPICOLON stage 2. In the joint analysis for both stages, results were only significant for rs3803185 and borderline significant for rs698 and rs2102302. The rs3803185 variant was not significantly associated with CRC risk in an external cohort (MCC-Spain), but it still showed some borderline significance in the pooled analysis of both cohorts.

*ARL11*, also known as *ARLTS1*(ADP-ribosylation factor-like tumor suppressor gene 1), is a tumor suppressor gene that belongs to the ARF family of the Ras superfamily of small GTPases that are known to be involved in multiple regulatory pathways altered in human carcinogenesis. It has been suggested that *ARL11*SNPs, especially rs3803185, may act as low penetrance variants in several neoplasms including CRC \[[@B6],[@B24],[@B32]\]. The *ADH1C*gene encodes for class I alcohol dehydrogenase, gamma subunit, which is a member of the alcohol dehydrogenase family. Members of this enzyme family metabolize a wide variety of substrates, including ethanol. There is a noticeable association between alcohol consumption and CRC risk \[[@B33]\], and it is plausible that this association could also be modified by germline variants in enzymes that metabolize ethanol. *GALNTL2*(UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-like 2), also known as *GALNT15*, is ubiquitously expressed in human tissues \[[@B34]\]. This gene has never been investigated in CRC susceptibility and it has only been reported to be studied as a genetic factor involved in longevity \[[@B35]\]. Chronic inflammation is in the etiology of CRC and release of large amount of cytokines and growth factors may influence the carcinogenesis process. The *IL6*(interleukin 6) gene, among others, has been analyzed in previous independent genetic association studies and it is an *a priori*attractive candidate for genetic susceptibility to CRC \[[@B15],[@B16]\].

Finally, as limitations of our study, it should be commented that our cohort sample size may probably be not large enough to reach stronger conclusions for the analyzed variants. However, our study (1,416 CRC cases and 1,424 controls for the EPICOLON cohorts) had an estimated 80% power to detect an OR as low as 1.3 with a MAF of 0.30, and 1.34 for a MAF down to 0.20, assuming a log-additive model and α = 0.05. Also, since we did not follow a GWAS strategy, our results apply only for the selected SNPs. Nevertheless, gene/SNP selection was biased to include those with previously published positive association results for CRC risk or those mucin SNPs with a putative functional effect.

In summary, none of the 28 SNPs analyzed in our study could be associated with CRC risk. However, variants in *ARL11*, *ADH1C*, *GALNTL2*and *IL6*may have an effect on CRC risk. Mucins and GALNTs, included in the mucin gene family, have been found deregulated in CRC and other neoplasms, and they are interesting candidates for CRC genetic susceptibility \[[@B27]\]. Since they have not been previously evaluated and despite our mostly negative results, we consider that genetic variation in the mucin gene family should be further explored in larger CRC cohorts in order to draw more solid conclusions. Also, additional case-control studies in larger CRC cohorts and meta-analyses could be useful to confirm or refute the role of *ARL11*, *ADH1C*, *GALNTL2*and *IL6*variants in CRC susceptibility.

Conclusions
===========

None of the 28 SNPs analyzed in our study could be associated with CRC risk. However, *ARL11*, *ADH1C*, *GALNTL2*and *IL6*genetic variants may have an effect on CRC risk. Further validation and meta-analyses should be undertaken in larger CRC cohorts.
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Hospital 12 de Octubre, Madrid: Juan Diego Morillas (local coordinator), Raquel Muñoz, Marisa Manzano, Francisco Colina, Jose Díaz, Carolina Ibarrola, Guadalupe López, Alberto Ibáñez; Hospital Clínic, Barcelona: Antoni Castells (local coordinator), Virgínia Piñol, Sergi Castellví-Bel, Francesc Balaguer, Victoria Gonzalo, Teresa Ocaña, María Dolores Giráldez, Maria Pellisé, Anna Serradesanferm, Leticia Moreira, Miriam Cuatrecasas, Josep M. Piqué; Hospital Clínico Universitario, Zaragoza: Ángel Lanas (local coordinator), Javier Alcedo, Javier Ortego; Hospital Cristal-Piñor, Complexo Hospitalario de Ourense: Joaquin Cubiella (local coordinator), Mª Soledad Díez, Mercedes Salgado, Eloy Sánchez, Mariano Vega; Hospital del Mar, Barcelona: Montserrat Andreu (local coordinator), Anna Abuli, Xavier Bessa, Mar Iglesias, Agustín Seoane, Felipe Bory, Gemma Navarro, Beatriz Bellosillo; Josep Mª Dedeu, Cristina Álvarez, Begoña Gonzalez; Hospital San Eloy, Baracaldo and Hospital Donostia, CIBERehd, University of Country Basque, San Sebastián: Luis Bujanda (local coordinator) Ángel Cosme, Inés Gil, Mikel Larzabal, Carlos Placer, María del Mar Ramírez, Elisabeth Hijona, Jose M. Enríquez-Navascués y Jose L. Elosegui; Hospital General Universitario de Alicante: Artemio payá (EPICOLON I local coordinator), Rodrigo Jover (EPICOLON II local coordinator), Cristina Alenda, Laura Sempere, Nuria Acame, Estefanía Rojas, Lucía Pérez-Carbonell; Hospital General de Granollers: Joaquim Rigau (local coordinator), Ángel Serrano, Anna Giménez; Hospital General de Vic: Joan Saló (local coordinator), Eduard Batiste-Alentorn, Josefina Autonell, Ramon Barniol; Hospital General Universitario de Guadalajara and Fundación para la Formación e Investigación Sanitarias Murcia: Ana María García (local coordinator), Fernando Carballo, Antonio Bienvenido, Eduardo Sanz, Fernando González, Jaime Sánchez, Akiko Ono; Hospital General Universitario de Valencia: Mercedes Latorre (local coordinator), Enrique Medina, Jaime Cuquerella, Pilar Canelles, Miguel Martorell, José Ángel García, Francisco Quiles, Elisa Orti; CHUVI-Hospital Meixoeiro, Vigo: EPICOLON I: Juan Clofent (local coordinator), Jaime Seoane, Antoni Tardío, Eugenia Sanchez. EPICOLON II Mª Luisa de Castro (local coordinator), Antoni Tardío, Juan Clofent, Vicent Hernández; Hospital Universitari Germans Trias i Pujol, Badalona and Section of Digestive Diseases and Nutrition, University of Illinois at Chicago, IL, USA.: Xavier Llor (local coordinator), Rosa M. Xicola, Marta Piñol, Mercè Rosinach, Anna Roca, Elisenda Pons, José M. Hernández, Miquel A. Gassull; Hospital Universitari Mútua de Terrassa: Fernando Fernández-Bañares (local coordinator), Josep M. Viver, Antonio Salas, Jorge Espinós, Montserrat Forné, Maria Esteve; Hospital Universitari Arnau de Vilanova, Lleida: Josep M. Reñé (local coordinator), Carmen Piñol, Juan Buenestado, Joan Viñas; Hospital Universitario de Canarias: Enrique Quintero (local coordinator), David Nicolás, Adolfo Parra, Antonio Martín; Hospital Universitario La Fe, Valencia: Lidia Argüello (local coordinator), Vicente Pons, Virginia Pertejo, Teresa Sala; Hospital Sant Pau, Barcelona: Dolors Gonzalez (local coordinator) Eva Roman, Teresa Ramon, Maria Poca, Mª Mar Concepción, Marta Martin, Lourdes Pétriz; Hospital Xeral Cies, Vigo: Daniel Martinez (local coordinator); Fundacion Publica Galega de Medicina Xenomica (FPGMX), CIBERER, Genomic Medicine Group-University of Santiago de Compostela, Santiago de Compostela, Galicia, Spain: Ángel Carracedo (local coordinator), Clara Ruiz-Ponte, Ceres Fernández-Rozadilla, Mª Magdalena Castro; Hospital Universitario Central de Asturias: Sabino Riestra (local coordinator), Luis Rodrigo; Hospital de Galdácano, Vizcaya: Javier Fernández (local coordinator), Jose Luis Cabriada; Fundación Hospital de Calahorra (La Rioja) La Rioja: Luis Carreño (local coordinator), Susana Oquiñena, Federico Bolado; Hospital Royo Villanova, Zaragoza: Elena Peña (local coordinator), José Manuel Blas, Gloria Ceña, Juan José Sebastián; Hospital Universitario Reina Sofía, Córdoba: Antonio Naranjo (local coordinator).
